EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial

Apolline Grangeon, Martin Connock, Peter Auguste iD, Jean François Obadia, Maurice Enriquez-Sarano, Benjamin Essayagh iD, Xavier Armoiry iD

ESC Heart Failure · 27.08.2026 · 13 (5)

DOI: 10.1093/eschf/xvag137 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, online erschienen am 13.05.2026. Verfasst von Apolline Grangeon und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Claude Bernard ISPB, Vyoo Agency, Lyon, France. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Cost-Benefit Analysis, Heart Valve Prosthesis Implantation, Tricuspid Valve. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Doctor of Pharmacy (PharmD) thesis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Evoque™ transcatheter tricuspid valve replacement (TTVR) system demonstrated superiority over optimal medical treatment (OMT) in the TRISCEND II trial. We aimed to evaluate the cost-effectiveness of TTVR in patients with severe Tricuspid Regurgitation (TR) from the French healthcare perspective.

Methods

A state-transition Markov model was developed to assess the cost-effectiveness of Evoque™ TTVR versus OMT alone over a lifetime horizon. The modelled cohort reflected the TRISCEND II population. Health states were defined by TR severity (none/trace, mild, moderate, severe) and death. Transition probabilities, adverse events, and hospitalization rates were informed by TRISCEND II. Long-term survival outcomes were extrapolated by TR severity using published data. Utilities were estimated from the NYHA class distribution. Costs and health outcomes were discounted at 2.5% annually.

Results

Evoque™ was associated with an incremental 1.76 life-years gained (LYG) and 1.63 quality-adjusted LYG (QALY). Incremental costs were €39 382 driven by device acquisition and procedure costs, resulting in an incremental cost-effectiveness ratio (ICERs) of €22 327/LYG and €24 109/QALY gained. Assuming no mortality difference in extrapolations, the ICER would increase to €86 428/QALY (+258%). The model was highly sensitive to assumptions on time horizon, utility, discount rate, and post-trial mortality extrapolation, leading to major uncertainty.

Conclusion

Evoque™ may represent a cost-effective strategy in severe TR patients; however, this should be interpreted with caution, as results rely heavily on extrapolated data and are subject to high structural and parameter uncertainty. The projected long-term benefits are largely model driven rather than empirically demonstrated, emphasizing the need for extended follow-up data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tricuspid Valve InsufficiencyCost-Benefit AnalysisHeart Valve Prosthesis ImplantationTricuspid ValveHumansCost-Effectiveness AnalysisSeverity of Illness IndexFemaleMaleAgedFollow-Up StudiesFrance

Stichwörter der Autor:innen

Cost-effectivenessEvoque™FranceHealth economicsTranscatheter tricuspid valve replacementTricuspid regurgitation

Autor:innen und Institutionen

  • University Claude Bernard ISPB, Vyoo Agency, Lyon, France.
  • University of Birmingham, Centre for Evidence and Implementation Science (CEIS), Health Services Management Centre School of Social Policy and Society, College of Social Sciences, Birmingham, UK.
  • Hopital Cardiovasculaire Louis Pradel, Chirurgie Cardio-Vasculaire et Transplantation Cardiaque, Hospices Civils de Lyon and Claude Bernard University, Lyon, France.
  • Abbott Northwestern Hospital, Minneapolis, MN, USA.
  • Department of Echocardiography, Cardio X Clinic, Cannes, France.
  • Pharmacy Department and Laboratoire MATEIS UMR CNRS 5510, Hospices Civils de Lyon and Claude Bernard University, 8 avenue Rockefeller, Lyon 69008, France.

ORCID-Profile: Peter Auguste, Benjamin Essayagh, Xavier Armoiry

Förderung

  • Doctor of Pharmacy (PharmD) thesis

Zitieren

APA

Grangeon, A., Connock, M., Auguste, P., Obadia, J. F., Enriquez-Sarano, M., Essayagh, B., & Armoiry, X. (2026). Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial. ESC Heart Failure, 13(5). https://doi.org/10.1093/eschf/xvag137

Vancouver

Grangeon A, Connock M, Auguste P, Obadia JF, Enriquez-Sarano M, Essayagh B, et al. Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial. ESC Heart Failure. 2026;13(5). doi:10.1093/eschf/xvag137

BibTeX
@article{Grangeon2026,
  author = {Grangeon, Apolline and Connock, Martin and Auguste, Peter and Obadia, Jean François and Enriquez-Sarano, Maurice and Essayagh, Benjamin and Armoiry, Xavier},
  title = {Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {5},
  doi = {10.1093/eschf/xvag137}
}
Kostenlos starten →